Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

JOINTSTEM

Phase 3Small molecule

JOINTSTEM is one of 82 small molecule programs targeting Arthroscopy. It is currently in Phase 3.

3

Indications

8

Total Trials

3

Active Trials

81

Competitors

Pipeline

Status by Indication[3][1]

Indication

ArthroscopyNot yet recruiting

Clinical TrialActive, not recruiting

Osteoarthritis, KneeActive, not recruiting

ArthroscopyPreclinical

Not yet recruiting

Clinical TrialPhase 3

Active, not recruiting

Osteoarthritis, KneePreclinical

Active, not recruiting

Competition

Competitive Landscape

127 competitors in Clinical Trial

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Venclexta

Avelox

Paraplatin

Opzelura

DDizal Pharmaceuticals

Potassium Iodide

MMeda Pharmaceuticals

Ablysinol

Nascobal

GGrupo Espanol de Tumores Neuroendocrinos

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

JOINTSTEM

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalActive, not recruiting

Osteoarthritis, Knee

NCT04368806

Q4 2027

Phase 3Active, not recruiting

Clinical Trial

NCT04427930

Q4 2029

N/ANot yet recruiting

Arthroscopy

NCT04825730

Clinical

Trials by Indication[1]

Arthroscopy2 trials

Investigator Initiated Trial to Evaluate Cartilage Regeneration by Arthroscopy After JOINTSTEM Administration

Unknown status·RR-Bio·N/A·NCT04821102·21 enrolled

Follow-up Study for Participants of Jointstem Investigator Initiated Trial by Arthroscopy

Not yet recruiting·RR-Bio·N/A·NCT04825730·14 enrolled

Clinical Trial2 trials

Follow-up Study for Participants Jointstem Clinical Trial

Completed·RR-Bio·Phase 2·NCT03509025·11 enrolled

Follow-up Study for Participants of Jointstem Phase 3 Clinical Trial

Active, not recruiting·RR-Bio·Phase 3·NCT04427930·129 enrolled

Osteoarthritis2 trials

A Phase 3 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis

Completed·RR-Bio·Phase 3·NCT03990805·260 enrolled

A Phase 2 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis

Completed·NNature Cell Co. Ltd.·Phase 2·NCT02674399·28 enrolled

Arthritis1 trial

Clinical Trial to Evaluate Efficacy and Safety of JOINTSTEM in Patients With Degenerative Arthritis

Completed·RR-Bio·Phase 2·NCT02658344·24 enrolled

Osteoarthritis, Knee1 trial

A 48-Weeks, Phase 2b/3a, Double-Blind, Randomized, Placebo Controlled, Multi-center, Superiority Study to Evaluate the Efficacy and Safety of JointStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells in Patients Diagnosed as Knee Osteoarthritis

Active, not recruiting·NNature Cell Co. Ltd.·Preclinical·NCT04368806·173 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for JOINTSTEM. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JOINTSTEM compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JOINTSTEM. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — R-Bio company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RR-Bio

Related News